Evidence map›Paper›PMID 41728983›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.

Georgina Maalouf, Bérangère Arnould, Olivier Espitia, Hubert Deboysson, Maxime Samson, Arnaud Hot, Eric Liozon, Simon Parreau, Christian Lavigne, Valentin Lacombe and 27 more

Abstract readMulticenter Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Georgina MaaloufSorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, and Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-4554-1922
Bérangère ArnouldDepartment of Internal Medicine, CHU Rouen, Rouen, France.
Olivier EspitiaDepartment of Vascular Medicine, CHU Nantes, Nantes, France.ORCID https://orcid.org/0000-0003-0821-9990
Hubert DeboyssonDepartment of Internal Medicine, CHU Caen, Caen, France.ORCID https://orcid.org/0000-0001-9083-8365
Maxime SamsonInternal Medicine and Systemic Disease Unit, CHU Dijon, Dijon, Burgundy, France.
Arnaud HotDepartment of Internal Medicine, Hôpital Edouard-Herriot, Lyon, France.
Eric LiozonDepartment of Internal Medicine, CHU Limoges, Limoges, France.
Simon ParreauDepartment of Internal Medicine, Hôpital Dupuytren, Limoges, France.
Christian LavigneMédecine interne et polyvalente, CH du Haut-Anjou, Chateau-Gontier; Médecine interne, CHU d'Angers.
Valentin LacombeMédecine interne et polyvalente, CH du Haut-Anjou, Chateau-Gontier; Médecine interne, CHU d'Angers.
Jean-Francois AlexandraDepartment de Médecine Interne-Immunologie Clinique, CHU d'Angers, Angers, France, Centre National de Référence Maladies Autoimmunes Systémiques Rares CeRAINOM-Angers.
Thomas ThibaultInternal Medicine and Systemic Disease Unit, CHU Dijon, Dijon, Burgundy, France.
Laurent ChicheDepartment of Vascular Surgery, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Julien GaudricDepartment of Vascular Surgery, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Alban RedheuilDepartment of Vascular and Interventional Radiology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Matheus VieiraSorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, and Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.
Matthieu GrohDepartment of Internal Medicine, Hôpital Foch, Suresnes, France.ORCID https://orcid.org/0000-0003-0810-136X
Cécile-Audrey DurelDepartment of Internal Medicine, Hôpital Edouard-Herriot, Lyon, France.ORCID https://orcid.org/0000-0003-2878-5017
Thibaud ChazalDepartment of Internal Medicine, Hôpital Fondation Adolphe-de-Rothschild, Paris, France.ORCID https://orcid.org/0000-0001-5114-3093
Chloé ComarmondDepartment of Internal Medicine, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Nadine Magy-BertrandDepartment of Internal Medicine, CHRU Jean-Minjoz, Besançon, France.
Stéphane VinzioDepartment of Internal Medicine, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France.
Lionel MartzolffDepartment of Internal Medicine, Groupe Hospitalier Région Mulhouse et Sud Alsace, Hôpital Emile-Muller, Mulhouse, France.
Pierre Lozac'hDepartment of Internal Medicine, CH Le Mans, Le Mans, France.
Rodérau OuthDepartment of Internal Medicine, CHU Grabiel-Montpied, Clermont-Ferrand, France.
Jérémy ClémentDepartment of Internal Medicine, CH de Blois, Blois, France.
Pierre DuffauDepartment of Internal Medicine, CHU de Bordeaux, Bordeaux, France.
Anael DumontDepartment of Internal Medicine, CHU Caen, Caen, France.ORCID https://orcid.org/0000-0003-1105-7662
Sebastien HumbertDepartment of Internal medicine, Centre Hospitalier Louis Pasteur, Dole, France.
Constance GuillaudDepartment of Internal Medicine, Hôpital Henri-Mondor, Créteil, France.
Azeddine DellalDepartment of Rheumatology, GHJ Le Raincy-Montfermeil, Montfermeil, France.
Grégory PugnetDepartment of Internal Medicine and Clinical Immunology, CHU Rangueil, Toulouse, France.
Valérie Devauchelle-PensecDepartment of Rheumatology, Hôpital de La Cavale-Blanche, Brest, France.ORCID https://orcid.org/0000-0003-0432-825X
Patrice CacoubSorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, and Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-6727-4992
Lucie BiardDepartment of Biostatistics, Hôpital Saint Louis, Paris.
David SaadounSorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, and Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.
GEFA (French Study Group for Large Vessel Vasculitis)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLarge vessel-vasculitis (LVV) accounts for up to 70% of patients with giant cell arteritis (GCA). Stenotic involvement in GCA-LVV remains largely unknown. The purpose of this study was to assess the long-term outcome and prognosis of GCA with stenotic LVV.

methodsThis was a retrospective multicenter study of 3,149 patients with GCA, including 198 (6.3%) with stenotic LVV. Hierarchical clustering on principal components was performed on baseline arterial localizations and logistic regression assessed factors associated with vascular complications.

resultsStenotic LVV affected mostly the subclavian artery (63%), the carotid artery (58%), vertebral artery (37%), and axillary artery (33%), followed by the femoral artery (30%) and mesenteric arteries (13%). Stroke (31%) was the main complication, followed by limb ischemia (21%), myocardial infarction (4%), and mesenteric ischemia (2%). Cumulative incidence of vascular complications was 13.1% (95% confidence interval [CI] 8.9-18.3), 17.3% (95% CI 12.3-22.9), and 19.5% (95% CI 14.3-25.4), at 1, 5, and 10 years, respectively. Hierarchical clustering analysis identified three clusters among which cluster 1 (n = 123; 62%) included older patients with more arteritic anterior ischemic optic neuropathy (P = 0.04), vertebral artery stenosis, and a higher mortality rate (P < 0.044). In multivariate analysis, age at diagnosis (hazard ratio [HR] 1.06, 95% CI 1.03-1.10; P = 0.0004) and vertebral involvement (HR 1.87, 95% CI 1.03-3.40; P = 0.039) were significantly associated with higher risk of vascular complication.

conclusionStenotic LVV accounts for less than 10% of GCA and is associated with poor vascular prognosis.

Indexed as

Giant Cell ArteritisMyocardial InfarctionStrokeAgedAged, 80 and overAxillary ArteryConstriction, PathologicFemaleFemoral ArteryHumansIschemiaMaleMesenteric ArteriesMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID41728983
PMCPMC13507598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.